---
title: "VK2735 in Chronic weight management: VANQUISH-1"
description: "Formulary evidence on VK2735 in Chronic weight management: VANQUISH-1. Covers Objective, Location and study date, Study design, Eligibility criteria, Treatment, Study outcomes, and 3 further headings. 39 evidence topics quoted from 16 sources."
canonical: "https://www.evicenter.com/drugs/vk2735--chronic-weight-management/clinical-evidence/vanquish-1"
published: "2026-11-15T21:45:47-05:00"
modified: "2026-11-15T21:45:47-05:00"
---

# VK2735 in Chronic weight management: VANQUISH-1

<a id="heading-3.1.1"></a>

## 3.1.1 VANQUISH-1

<a id="heading-3.1.1.1"></a>

### 3.1.1.1 Objective

<a id="topic-3.1.1.1-1"></a>

#### Study objective in the design poster

> “VANQUISH-1 will evaluate the weight loss efficacy as well as safety, tolerability, pharmacodynamic effects, and pharmacokinetics of VK2735”

Source: [Modesto et al. (2025b)](https://vikingtherapeutics.com/wp-content/uploads/2026/03/VANQUISH-1-Design-Phase-3-Trial-of-Subcutaneous-VK2735-in-Adults-with-Overweight-or-Obesity.pdf)

<a id="topic-3.1.1.1-2"></a>

#### Study objective in the ClinicalTrials.gov record

> “This is a phase 3, multicenter, 78-week randomized, double-blind, placebo-controlled, parallel arm study that will evaluate the weight loss efficacy as well as safety, tolerability, pharmacodynamic effects, and pharmacokinetics of VK2735 in adults who are obese (BMI ≥30 kg/m2) or overweight (BMI ≥27 kg/m2) with one or more weight related comorbid condition without Type 2 Diabetes.”

Source: [ClinicalTrials.gov NCT07104500](https://clinicaltrials.gov/study/NCT07104500)

<a id="topic-3.1.1.1-3"></a>

#### Role of the trial in the phase 3 program

> “The VANQUISH Phase 3 program includes two studies evaluating VK2735: one in adults with obesity and one in obese or overweight adults with type 2 diabetes.”

Source: [Viking Therapeutics VANQUISH initiation release (2025)](https://ir.vikingtherapeutics.com/2025-06-25-Viking-Therapeutics-Announces-Initiation-of-Phase-3-Obesity-Clinical-Program-with-GLP-1-GIP-Agonist-VK2735)

<a id="heading-3.1.1.2"></a>

### 3.1.1.2 Location and Study Date

<a id="topic-3.1.1.2-1"></a>

#### Study dates and status in the ClinicalTrials.gov record

> “Study Start (Actual) 2025-06-23”
> “Primary Completion (Estimated) 2027-07-01”
> “Study Completion (Estimated) 2027-08-01”
> “First Posted 2025-08-05”
> “Last Update Posted 2025-11-24”
> “Active, not recruiting”

Source: [ClinicalTrials.gov NCT07104500](https://clinicaltrials.gov/study/NCT07104500)

<a id="topic-3.1.1.2-2"></a>

#### Number of locations in the ClinicalTrials.gov record

> “This study has 137 locations”

Source: [ClinicalTrials.gov NCT07104500](https://clinicaltrials.gov/study/NCT07104500)

<a id="topic-3.1.1.2-3"></a>

#### Number of randomizing sites in the baseline poster

> “A total of 4660 participants were randomized from 138 US study sites”

Source: [Wyatt et al. (2026)](https://vikingtherapeutics.com/wp-content/uploads/2026/05/VANQUISH-1-Phase-3-Trial-with-Enrollment-of-a-Diverse-Population-to-Test-Efficacy-of-Subcutaneous-VK2735-in-Adult-Participants-with-Obesity-or-Overweight-With-Weight-Related-Comorbidity.pdf)

<a id="topic-3.1.1.2-4"></a>

#### Initiation and completion of enrollment

> “Viking Therapeutics, Inc. (Viking) (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced the completion of patient enrollment in its Phase 3 VANQUISH-1 clinical trial of subcutaneous VK2735”

Source: [Viking Therapeutics VANQUISH-1 enrollment release (2025)](https://ir.vikingtherapeutics.com/2025-11-19-Viking-Therapeutics-Announces-Completion-of-Enrollment-in-Phase-3-VANQUISH-1-Trial-of-VK2735)

> “Enrollment completed in 4Q25”

Source: [Viking Therapeutics corporate presentation (2026)](https://ir.vikingtherapeutics.com/download/Viking+Therapeutics+Corporate+Presentation+November+2026.pdf)

<a id="topic-3.1.1.2-5"></a>

#### Expected completion and timing of data

> “During the third quarter, both VANQUISH studies continued to advance on track. The company expects these studies to be completed in 2027.”

Source: [Viking Therapeutics third quarter 2026 results release (2026)](https://ir.vikingtherapeutics.com/2026-10-28-Viking-Therapeutics-Reports-Third-Quarter-2026-Financial-Results-and-Provides-Corporate-Update)

> “Data Expected 2H27”

Source: [Viking Therapeutics corporate presentation (2026)](https://ir.vikingtherapeutics.com/download/Viking+Therapeutics+Corporate+Presentation+November+2026.pdf)

> “With the SubQ, we think the phase III data, we're looking at a rough estimate here, second half 2027.”
> “The cadence of the SubQ data, we would expect the VANQUISH-1 study to read out first since that was enrolled first.”

Source: [Viking Therapeutics Jefferies conference transcript (2026)](https://stockanalysis.com/stocks/vktx/transcripts/678533-jefferies-global-healthcare-conference-2026/)

<a id="heading-3.1.1.3"></a>

### 3.1.1.3 Study Design

<a id="topic-3.1.1.3-1"></a>

#### Design, duration, randomization ratio, and stratification

> “VANQUISH-1 (NCT07104500) is a Phase 3, multicenter, randomized, double-blind, placebo-controlled, parallel arm study”
> “The duration of the study is 78 weeks, with a 6-week follow-up period”
> “Participants with obesity or overweight will be randomized 3:2:3:3 to the study arms below and will be stratified by sex”

Source: [Modesto et al. (2025b)](https://vikingtherapeutics.com/wp-content/uploads/2026/03/VANQUISH-1-Design-Phase-3-Trial-of-Subcutaneous-VK2735-in-Adults-with-Overweight-or-Obesity.pdf)

<a id="topic-3.1.1.3-2"></a>

#### Official title in the ClinicalTrials.gov record

> “A Phase 3 Randomized, Double-Blind, Placebo-Controlled, 78-Week Efficacy and Safety Study of VK2735 Administered Subcutaneously for Weight Management in Participants Without Type 2 Diabetes Who Are Obese, or Overweight With at Least One Weight-related Comorbid Condition”

Source: [ClinicalTrials.gov NCT07104500](https://clinicaltrials.gov/study/NCT07104500)

<a id="topic-3.1.1.3-3"></a>

#### Allocation of fewer participants to the lowest dose

> “It was higher than what we'd explored in the phase II study.”
> “And they didn't have a problem with it, provided that we had more randomized to those higher dose arms than the lower dose arms.”
> “Just the low, the 7.5 is a little bit smaller than the 12.5 and the 17.5.”

Source: [Viking Therapeutics J.P. Morgan conference transcript (2026)](https://stockanalysis.com/stocks/vktx/transcripts/537697-44th-annual-j-p-morgan-healthcare-conference/)

<a id="topic-3.1.1.3-4"></a>

#### Diversity plan

> “Developed to promote broad, inclusive participation to improve the relevance of trial outcomes”
> “Enrollment goals specified to achieve inclusive trial participation reflective of the real-world demographic”

Source: [Modesto et al. (2025b)](https://vikingtherapeutics.com/wp-content/uploads/2026/03/VANQUISH-1-Design-Phase-3-Trial-of-Subcutaneous-VK2735-in-Adults-with-Overweight-or-Obesity.pdf)

<a id="topic-3.1.1.3-5"></a>

#### Extension study after the 78-week treatment period

> “Following completion of the 78-week treatment period in both VANQUISH studies, participants are eligible to enroll in extension studies, enabling them to continue their treatment for up to an additional 52 weeks.”
> “In addition, the VANQUISH-1 extension study will include certain less-frequent dosing regimens, including every-other-week and monthly administration. The company anticipates the results of the extension studies to be available in 2028.”

Source: [Viking Therapeutics third quarter 2026 results release (2026)](https://ir.vikingtherapeutics.com/2026-10-28-Viking-Therapeutics-Reports-Third-Quarter-2026-Financial-Results-and-Provides-Corporate-Update)

> “Each study will include an extension portion that allows participants to continue treatment after completing the primary dosing period, including patients randomized to placebo for the initial 78-week treatment period.”

Source: [Viking Therapeutics ObesityWeek 2026 release (2026)](https://ir.vikingtherapeutics.com/2026-11-15-Viking-Therapeutics-Highlights-Clinical-Data-from-VK2735-Obesity-Program-at-ObesityWeek-R-2026)

> “Well, for the first question, we'll transition people at 78 weeks. It won't be a sort of a washout or anything like that out to 84. We plan to run the extension for 52 weeks.”

Source: [Viking Therapeutics first quarter 2026 earnings call transcript (2026)](https://stockanalysis.com/stocks/vktx/transcripts/555372-q1-2026/)

> “During the third quarter, both VANQUISH studies continued on track, and we expect the first patients to enter the extension periods in early 2027.”

Source: [Viking Therapeutics third quarter 2026 earnings call transcript (2026)](https://stockanalysis.com/stocks/vktx/transcripts/714458-q3-2026/)

<a id="heading-3.1.1.4"></a>

### 3.1.1.4 Eligibility Criteria

<a id="topic-3.1.1.4-1"></a>

#### Key inclusion and exclusion criteria in the design poster

> “Adults ≥18 years of age”
> “BMI ≥30 kg/m2 or”
> “BMI ≥27 kg/m2 and ≥1 weight-related co-morbid condition”
> “History of diabetes”
> “Prior or planned bariatric surgery”
> “Recent significant weight changes (≥5% within 3 months of screening)”
> “History of acute or chronic pancreatitis”
> “Impaired renal function”
> “Use of any GLP-1 RA or dual GLP-1/GIP receptor agonist or analogs within 6 months of screening”

Source: [Modesto et al. (2025b)](https://vikingtherapeutics.com/wp-content/uploads/2026/03/VANQUISH-1-Design-Phase-3-Trial-of-Subcutaneous-VK2735-in-Adults-with-Overweight-or-Obesity.pdf)

<a id="topic-3.1.1.4-2"></a>

#### Inclusion criteria in the ClinicalTrials.gov record

> “Age ≥18 years of age at the time of signing the informed consent”
> “Body mass index (BMI) ≥30 kg/m2 OR ≥27 kg/m2 with at least one weight-related co- morbid condition (treated or untreated)”
> “Weight-related co-morbid conditions include hypertension, dyslipidemia, obstructive sleep apnea or cardiovascular disease”
> “Cardiovascular disease includes, for example, ischemic cardiovascular disease, New York Heart Association (NYHA) Functional Class I-III heart failure”

Source: [ClinicalTrials.gov NCT07104500](https://clinicaltrials.gov/study/NCT07104500)

<a id="topic-3.1.1.4-3"></a>

#### Exclusion criteria in the ClinicalTrials.gov record

> “Self-reported body weight change of 5% or more within 3 months of screening”
> “Have or plan to have endoscopic and/or device-based therapy for obesity or have had device removal within the last 6 months prior to screening”
> “Current or past diagnosis of diabetes mellitus (including type 1, type 2, except gestational diabetes)”
> “Treatment with glucose-lowering agent(s) within 90 days before screening”
> “Personal or family history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia type 2 (MEN2)”
> “History of acute or chronic pancreatitis”

Source: [ClinicalTrials.gov NCT07104500](https://clinicaltrials.gov/study/NCT07104500)

<a id="heading-3.1.1.5"></a>

### 3.1.1.5 Treatment

<a id="topic-3.1.1.5-1"></a>

#### Treatment arms in the ClinicalTrials.gov record

| Arm | Description in the record |
| --- | --- |
| Placebo | “VK2735 Placebo Comparator Once Weekly” |
| Dose 1 | “VK2735 7.5mg Once Weekly” |
| Dose 2 | “VK2735 12.5mg Once Weekly” |
| Dose 3 | “VK2735 17.5mg Once Weekly” |
| Intervention | “VK2735 is a peptide GLP-1 and GIP dual agonist administered Once Weekly” |

Source: [ClinicalTrials.gov NCT07104500](https://clinicaltrials.gov/study/NCT07104500)

<a id="topic-3.1.1.5-2"></a>

#### Subcutaneous formulation: dose arms and lifestyle counseling

> “Matched placebo”
> “7.5 mg weekly SC VK2735”
> “12.5 mg weekly SC VK2735”
> “17.5 mg weekly SC VK2735”
> “All groups: Counseling for reduced calorie diet and exercise”

Source: [Modesto et al. (2025b)](https://vikingtherapeutics.com/wp-content/uploads/2026/03/VANQUISH-1-Design-Phase-3-Trial-of-Subcutaneous-VK2735-in-Adults-with-Overweight-or-Obesity.pdf)

<a id="topic-3.1.1.5-3"></a>

#### Subcutaneous formulation: dose titration from 1.25 mg

> “So four arms, placebo, 7.5, 12.5, and 17.5. All of these will go with a 2.5 mg uptick in titration, but they will all also start at 1.25 mg. So two weeks at 1.25 and then four weeks at 2.5, four weeks at 5, and so on up to 17.5. And when you get to 17.5, that's when the 52-week stable dose window starts.”

Source: [Viking Therapeutics J.P. Morgan conference transcript (2026)](https://stockanalysis.com/stocks/vktx/transcripts/537697-44th-annual-j-p-morgan-healthcare-conference/)

> “What we did in the phase III is we've started people at 1.25 mgs for two weeks, then go up to 2.5 mgs for four, and you go up in 2.5 mg increments in four-week blocks.”
> “The thinking is there that maybe you have this little teaser dose, low dose, maybe that helps with some of the known GI side effects, your nausea, vomiting, constipation, diarrhea, that are known to happen when you start a GLP-1 based therapy.”

Source: [Viking Therapeutics Morgan Stanley conference transcript (2026)](https://stockanalysis.com/stocks/vktx/transcripts/744429-morgan-stanley-24th-annual-global-healthcare-conference/)

<a id="topic-3.1.1.5-4"></a>

#### Subcutaneous formulation: transition from vial and syringe to autoinjector

> “Both the VANQUISH-1 and VANQUISH-2 studies were initiated using a vial and syringe for administration of VK2735.”
> “We are happy to report that this study was successfully completed, enabling the introduction of the autoinjector for all participants in the VANQUISH program.”

Source: [Viking Therapeutics fourth quarter 2025 earnings call transcript (2026)](https://stockanalysis.com/stocks/vktx/transcripts/401860-q4-2025/)

> “I think certainly with VANQUISH 1, everybody's now on an auto-injector.”
> “Your clinic visits drop from four per month to one per month.”

Source: [Viking Therapeutics second quarter 2026 earnings call transcript (2026)](https://stockanalysis.com/stocks/vktx/transcripts/657331-q2-2026/)

<a id="topic-3.1.1.5-5"></a>

#### Prohibited use of other incretin therapies

> “It's certainly not allowed in the study. A GLP-1 use is an exclusion criterion. We haven't heard from our sites or investigators that this is an issue.”

Source: [Viking Therapeutics second quarter 2026 earnings call transcript (2026)](https://stockanalysis.com/stocks/vktx/transcripts/657331-q2-2026/)

<a id="heading-3.1.1.6"></a>

### 3.1.1.6 Study Outcomes

<a id="heading-3.1.1.6.1"></a>

#### 3.1.1.6.1 Rationale for Using Percent Change in Body Weight as the Primary Endpoint

<a id="topic-3.1.1.6.1-1"></a>

##### Primary endpoint

> “Percentage change in body weight from baseline for participants receiving VK2735 after 78 weeks of treatment”

Source: [ClinicalTrials.gov NCT07104500](https://clinicaltrials.gov/study/NCT07104500)

> “The primary endpoint of the trial is the percent change in body weight from baseline for participants receiving VK2735 as compared to placebo after 78 weeks of treatment.”

Source: [Viking Therapeutics VANQUISH-1 enrollment release (2025)](https://ir.vikingtherapeutics.com/2025-11-19-Viking-Therapeutics-Announces-Completion-of-Enrollment-in-Phase-3-VANQUISH-1-Trial-of-VK2735)

<a id="topic-3.1.1.6.1-2"></a>

##### Secondary endpoint: categorical weight reduction

> “Percentage of participants who achieve ≥5%, ≥10%, ≥15% and ≥20% body weight reduction after 78 weeks of treatment”

Source: [ClinicalTrials.gov NCT07104500](https://clinicaltrials.gov/study/NCT07104500)

<a id="topic-3.1.1.6.1-3"></a>

##### Additional outcomes: function, cardiometabolic health, mental health, and work productivity

> “Physical functioning (SF-36 v2, IWQoL)”
> “hsCRP, MACE, ALT, AST, eGFR”
> “Work Productivity & Activity Impairment”
> “Measures that influence treatment adherence and persistence will also be collected (e.g., health-related quality of life, physical and mental well-being, work productivity, and treatment satisfaction)”

Source: [Modesto et al. (2025b)](https://vikingtherapeutics.com/wp-content/uploads/2026/03/VANQUISH-1-Design-Phase-3-Trial-of-Subcutaneous-VK2735-in-Adults-with-Overweight-or-Obesity.pdf)

> “Exploratory endpoints: Changes in function, metabolic health, mental health, productivity”

Source: [Viking Therapeutics corporate presentation (2026)](https://ir.vikingtherapeutics.com/download/Viking+Therapeutics+Corporate+Presentation+November+2026.pdf)

<a id="topic-3.1.1.6.1-4"></a>

##### Rationale stated in the design poster

> “Studies have shown that reduction of excess body weight can reduce morbidity and mortality, which is correlated with the magnitude of weight loss”

Source: [Modesto et al. (2025b)](https://vikingtherapeutics.com/wp-content/uploads/2026/03/VANQUISH-1-Design-Phase-3-Trial-of-Subcutaneous-VK2735-in-Adults-with-Overweight-or-Obesity.pdf)

<a id="topic-3.1.1.6.1-5"></a>

##### Regulatory basis for the primary endpoint and for responder analyses

> “The efficacy of a weight-reduction drug in adults should be assessed by analyses of mean”
> “percentage change from baseline body weight in the investigational drug group versus the”
> “control group.”
> “In general, a drug is considered effective for weight reduction and maintenance in patients with”
> “obesity or overweight with comorbidities if, after 1 year of treatment at the maintenance dosage,”
> “the difference in mean percentage weight reduction between the investigational drug and control-”
> “treated groups is at least 5% and the difference is statistically significant.”
> “responder analyses for the evaluation of weight reduction are generally not recommended.”

Source: [FDA weight reduction draft guidance (2025)](https://www.fda.gov/media/71252/download)

<a id="heading-3.1.1.7"></a>

### 3.1.1.7 Statistical Analysis Description

<a id="heading-3.1.1.7.1"></a>

#### 3.1.1.7.1 Number of Participants (Planned and Analyzed)

<a id="topic-3.1.1.7.1-1"></a>

##### Planned enrollment

> “Approximately 4,500 participants will be randomized in the study”

Source: [Modesto et al. (2025b)](https://vikingtherapeutics.com/wp-content/uploads/2026/03/VANQUISH-1-Design-Phase-3-Trial-of-Subcutaneous-VK2735-in-Adults-with-Overweight-or-Obesity.pdf)

> “The VANQUISH-1 study will target enrollment of approximately 4500 adults who are obese (BMI ≥30 kg/m2) or who are overweight (BMI ≥27 kg/m2) with at least one weight-related co-morbid condition.”

Source: [Viking Therapeutics VANQUISH initiation release (2025)](https://ir.vikingtherapeutics.com/2025-06-25-Viking-Therapeutics-Announces-Initiation-of-Phase-3-Obesity-Clinical-Program-with-GLP-1-GIP-Agonist-VK2735)

<a id="topic-3.1.1.7.1-2"></a>

##### Planned participants per arm in the design poster

| Arm | Planned participants |
| --- | --- |
| Placebo | “n=1224” |
| VK2735 7.5 mg | “n=816” |
| VK2735 12.5 mg | “n=1224” |
| VK2735 17.5 mg | “n=1224” |

Source: [Modesto et al. (2025b)](https://vikingtherapeutics.com/wp-content/uploads/2026/03/VANQUISH-1-Design-Phase-3-Trial-of-Subcutaneous-VK2735-in-Adults-with-Overweight-or-Obesity.pdf)

<a id="topic-3.1.1.7.1-3"></a>

##### Enrollment reported after completion

> “The trial enrolled approximately 4,650 adults with obesity (BMI ≥30 kg/m2) or who are overweight (BMI ≥27 kg/m2) with at least one weight-related co-morbid condition.”

Source: [Viking Therapeutics VANQUISH-1 enrollment release (2025)](https://ir.vikingtherapeutics.com/2025-11-19-Viking-Therapeutics-Announces-Completion-of-Enrollment-in-Phase-3-VANQUISH-1-Trial-of-VK2735)

> “A total of 4660 participants were randomized from 138 US study sites”

Source: [Wyatt et al. (2026)](https://vikingtherapeutics.com/wp-content/uploads/2026/05/VANQUISH-1-Phase-3-Trial-with-Enrollment-of-a-Diverse-Population-to-Test-Efficacy-of-Subcutaneous-VK2735-in-Adult-Participants-with-Obesity-or-Overweight-With-Weight-Related-Comorbidity.pdf)

> “The VANQUISH-1 study enrolled approximately 4,500 patients within approximately five months of initiation.”

Source: [Viking Therapeutics third quarter 2026 results release (2026)](https://ir.vikingtherapeutics.com/2026-10-28-Viking-Therapeutics-Reports-Third-Quarter-2026-Financial-Results-and-Provides-Corporate-Update)

> “Enrolled more than 4,500 adults who are obese or overweight with at least one weight-related co-morbid condition”

Source: [Viking Therapeutics corporate presentation (2026)](https://ir.vikingtherapeutics.com/download/Viking+Therapeutics+Corporate+Presentation+November+2026.pdf)

<a id="heading-3.1.1.7.2"></a>

#### 3.1.1.7.2 Description of Analysis Sets

<a id="topic-3.1.1.7.2-1"></a>

##### Population analyzed for baseline characteristics

> “Analyze preliminary baseline demographic data from the randomized population of the VANQUISH-1 study”
> “Randomized VANQUISH-1 study population was compared with a nationally representative sample of US adults with a BMI ≥27 kg/m2 and no diagnosis of diabetes”
> “NHANES population did not necessarily have weight-related comorbid condition(s)”

Source: [Wyatt et al. (2026)](https://vikingtherapeutics.com/wp-content/uploads/2026/05/VANQUISH-1-Phase-3-Trial-with-Enrollment-of-a-Diverse-Population-to-Test-Efficacy-of-Subcutaneous-VK2735-in-Adult-Participants-with-Obesity-or-Overweight-With-Weight-Related-Comorbidity.pdf)

<a id="topic-3.1.1.7.2-2"></a>

##### Efficacy and safety analysis sets

No evidence found.

<a id="heading-3.1.1.8"></a>

### 3.1.1.8 Results

<a id="heading-3.1.1.8.1"></a>

#### 3.1.1.8.1 Participant Disposition

<a id="topic-3.1.1.8.1-1"></a>

##### Randomized participants

> “A total of 4660 participants were randomized from 138 US study sites”

Source: [Wyatt et al. (2026)](https://vikingtherapeutics.com/wp-content/uploads/2026/05/VANQUISH-1-Phase-3-Trial-with-Enrollment-of-a-Diverse-Population-to-Test-Efficacy-of-Subcutaneous-VK2735-in-Adult-Participants-with-Obesity-or-Overweight-With-Weight-Related-Comorbidity.pdf)

<a id="topic-3.1.1.8.1-2"></a>

##### Blinded discontinuation rate across the VANQUISH program

> “The discontinuation rate is tracking our expectations. It's blinded data, so it's really difficult to interpret why someone discontinues. But the overall rate is within what we expected when we designed the study.”

Source: [Viking Therapeutics third quarter 2026 earnings call transcript (2026)](https://stockanalysis.com/stocks/vktx/transcripts/714458-q3-2026/)

<a id="heading-3.1.1.8.2"></a>

#### 3.1.1.8.2 Baseline Characteristics

<a id="topic-3.1.1.8.2-1"></a>

##### Demographics and body size compared with NHANES

| Characteristic | VANQUISH-1 (N=4660) | NHANES |
| --- | --- | --- |
| Age, mean (SD), years | “50.4 (13.81)” | “47.6 (13.97)” |
| Age 65 years or older | “17%” | “19%” |
| Sex, female to male | “65%:35%” | “51%:49%” |
| Waist circumference, mean (SD), cm | “116.2 (16.13)” | “109.2 (11.35)” |
| BMI, mean (SD), kg/m2 | “38.3 (7.31)” | “33.7 (5.10)” |
| BMI 27 to less than 30 kg/m2 | “5%” | “33%” |
| BMI 30 to less than 35 kg/m2 | “33%” | “36%” |
| BMI 35 to less than 40 kg/m2 | “28%” | “16%” |
| BMI 40 kg/m2 or higher | “33%” | “15%” |

Source: [Wyatt et al. (2026)](https://vikingtherapeutics.com/wp-content/uploads/2026/05/VANQUISH-1-Phase-3-Trial-with-Enrollment-of-a-Diverse-Population-to-Test-Efficacy-of-Subcutaneous-VK2735-in-Adult-Participants-with-Obesity-or-Overweight-With-Weight-Related-Comorbidity.pdf)

<a id="topic-3.1.1.8.2-2"></a>

##### Age distribution compared with NHANES

| Age group, years | VANQUISH-1 | NHANES |
| --- | --- | --- |
| 18 to 34 | “15%” | “28%” |
| 35 to 44 | “21%” | “20%” |
| 45 to 54 | “24%” | “16%” |
| 55 to 64 | “23%” | “17%” |
| 65 to 74 | “15%” | “12%” |
| Over 75 | “3%” | “7%” |

Source: [Wyatt et al. (2026)](https://vikingtherapeutics.com/wp-content/uploads/2026/05/VANQUISH-1-Phase-3-Trial-with-Enrollment-of-a-Diverse-Population-to-Test-Efficacy-of-Subcutaneous-VK2735-in-Adult-Participants-with-Obesity-or-Overweight-With-Weight-Related-Comorbidity.pdf)

<a id="topic-3.1.1.8.2-3"></a>

##### Race and ethnicity compared with NHANES

| Race or ethnicity | VANQUISH-1 | NHANES |
| --- | --- | --- |
| Non-Hispanic White | “56%” | “60%” |
| Hispanic or Latino | “21%” | “18%” |
| Non-Hispanic Black | “17%” | “12%” |
| Non-Hispanic Asian | “2%” | “4%” |
| Other | “4%” | “6%” |

Source: [Wyatt et al. (2026)](https://vikingtherapeutics.com/wp-content/uploads/2026/05/VANQUISH-1-Phase-3-Trial-with-Enrollment-of-a-Diverse-Population-to-Test-Efficacy-of-Subcutaneous-VK2735-in-Adult-Participants-with-Obesity-or-Overweight-With-Weight-Related-Comorbidity.pdf)

<a id="topic-3.1.1.8.2-4"></a>

##### Baseline comorbidities

| Comorbidity | VANQUISH-1 (N=4660) |
| --- | --- |
| Prediabetes | “53%” |
| Hypertension | “39%” |
| Dyslipidemia | “36%” |
| Sleep apnea | “20%” |
| Osteoarthritis | “17%” |
| Asthma | “11%” |
| Metabolic dysfunction-associated fatty liver disease | “6%” |

Source: [Wyatt et al. (2026)](https://vikingtherapeutics.com/wp-content/uploads/2026/05/VANQUISH-1-Phase-3-Trial-with-Enrollment-of-a-Diverse-Population-to-Test-Efficacy-of-Subcutaneous-VK2735-in-Adult-Participants-with-Obesity-or-Overweight-With-Weight-Related-Comorbidity.pdf)

> “Prediabetes defined as fasting plasma glucose (FPG) 100 – 125 mg/dL or hemoglobin A1c (HbA1c) 5.7 – 6.4%.”
> “More than half of the VANQUISH-1 participants had evidence of prediabetes at baseline”

Source: [Wyatt et al. (2026)](https://vikingtherapeutics.com/wp-content/uploads/2026/05/VANQUISH-1-Phase-3-Trial-with-Enrollment-of-a-Diverse-Population-to-Test-Efficacy-of-Subcutaneous-VK2735-in-Adult-Participants-with-Obesity-or-Overweight-With-Weight-Related-Comorbidity.pdf)

<a id="topic-3.1.1.8.2-5"></a>

##### Baseline laboratory values

| Measurement, mean (SD) | VANQUISH-1 (N=4660) |
| --- | --- |
| HbA1c, % | “5.5 (0.40)” |
| Glucose, mg/dL | “97.2 (11.18)” |
| Insulin, µIU/mL | “16.4 (15.66)” |
| Total cholesterol, mg/dL | “192.6 (39.69)” |
| Triglyceride, mg/dL | “126.8 (61.85)” |
| hsCRP, mg/L | “6.0 (8.82)” |

Source: [Wyatt et al. (2026)](https://vikingtherapeutics.com/wp-content/uploads/2026/05/VANQUISH-1-Phase-3-Trial-with-Enrollment-of-a-Diverse-Population-to-Test-Efficacy-of-Subcutaneous-VK2735-in-Adult-Participants-with-Obesity-or-Overweight-With-Weight-Related-Comorbidity.pdf)

<a id="topic-3.1.1.8.2-6"></a>

##### Representativeness stated by the authors

> “A higher percentage of VANQUISH-1 participants are women vs the NHANES population”
> “Waist circumference and BMI category skewed higher in VANQUISH-1 population”
> “These preliminary baseline data demonstrate that the VANQUISH-1 population reflects a clinically relevant and diverse U.S. population with overweight or obesity without diabetes, supporting the generalizability of forthcoming efficacy and safety outcomes”

Source: [Wyatt et al. (2026)](https://vikingtherapeutics.com/wp-content/uploads/2026/05/VANQUISH-1-Phase-3-Trial-with-Enrollment-of-a-Diverse-Population-to-Test-Efficacy-of-Subcutaneous-VK2735-in-Adult-Participants-with-Obesity-or-Overweight-With-Weight-Related-Comorbidity.pdf)

<a id="heading-3.1.1.8.3"></a>

#### 3.1.1.8.3 Efficacy Results

No evidence found.

<a id="heading-3.1.1.8.4"></a>

#### 3.1.1.8.4 Health-related Quality of Life and Patient-reported Outcomes

No evidence found.

<a id="heading-3.1.1.8.5"></a>

#### 3.1.1.8.5 Safety Results

No evidence found.

<a id="heading-3.1.1.9"></a>

### 3.1.1.9 Study Limitations

<a id="topic-3.1.1.9-1"></a>

#### Summary: limitations evident from the available VANQUISH-1 documents

VANQUISH-1 is ongoing, with primary completion estimated for July 2027 and data expected in the second half of 2027, so no efficacy, patient-reported outcome, or safety result is available. All available information comes from the ClinicalTrials.gov record, company press releases, an investor presentation, company call and conference transcripts, and two congress posters authored by company employees with or without study investigators; no peer-reviewed design or results publication was identified, and the ClinicalTrials.gov record has posted no results.

Reported enrollment differs between documents: the registry lists an estimated 4,500 participants, the enrollment release reported “approximately 4,650 adults”, the baseline poster reported 4,660 participants randomized from 138 sites, and later releases and the investor presentation describe approximately or more than 4,500. The registry lists 137 locations.

The 7.5 mg arm was planned to be smaller than the other arms (816 compared with 1,224 planned participants per arm), so estimates for that dose will be less precise. The trial enrolled participants without diabetes in the United States and Puerto Rico only; 65% of participants were women, and the mean BMI was 38.3 kg/m2, higher than the 33.7 kg/m2 of the NHANES comparison population. Prior use of GLP-1 receptor agonists or dual GLP-1/GIP receptor agonists within 6 months of screening was excluded. The company describes the blinded discontinuation rate only qualitatively. The device changed during the trial, from vial and syringe to an autoinjector introduced in the first quarter of 2026. The extension study, which adds every-other-week and monthly regimens, is expected to report in 2028 and will not inform the primary 78-week analysis.

Source: [ClinicalTrials.gov NCT07104500](https://clinicaltrials.gov/study/NCT07104500); [Viking Therapeutics VANQUISH-1 enrollment release (2025)](https://ir.vikingtherapeutics.com/2025-11-19-Viking-Therapeutics-Announces-Completion-of-Enrollment-in-Phase-3-VANQUISH-1-Trial-of-VK2735); [Wyatt et al. (2026)](https://vikingtherapeutics.com/wp-content/uploads/2026/05/VANQUISH-1-Phase-3-Trial-with-Enrollment-of-a-Diverse-Population-to-Test-Efficacy-of-Subcutaneous-VK2735-in-Adult-Participants-with-Obesity-or-Overweight-With-Weight-Related-Comorbidity.pdf); [Modesto et al. (2025b)](https://vikingtherapeutics.com/wp-content/uploads/2026/03/VANQUISH-1-Design-Phase-3-Trial-of-Subcutaneous-VK2735-in-Adults-with-Overweight-or-Obesity.pdf); [Viking Therapeutics third quarter 2026 results release (2026)](https://ir.vikingtherapeutics.com/2026-10-28-Viking-Therapeutics-Reports-Third-Quarter-2026-Financial-Results-and-Provides-Corporate-Update); [Viking Therapeutics corporate presentation (2026)](https://ir.vikingtherapeutics.com/download/Viking+Therapeutics+Corporate+Presentation+November+2026.pdf); [Viking Therapeutics third quarter 2026 earnings call transcript (2026)](https://stockanalysis.com/stocks/vktx/transcripts/714458-q3-2026/); [Viking Therapeutics first quarter 2026 earnings call transcript (2026)](https://stockanalysis.com/stocks/vktx/transcripts/555372-q1-2026/)

## Related pages
- [VK2735: Chronic weight management](https://www.evicenter.com/drugs/vk2735--chronic-weight-management) · [Markdown](https://www.evicenter.com/drugs/vk2735--chronic-weight-management.md)
- [VK2735 in Chronic weight management: Terms and abbreviations](https://www.evicenter.com/drugs/vk2735--chronic-weight-management/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/vk2735--chronic-weight-management/terms-and-abbreviations.md)
- [VK2735: Chronic weight management](https://www.evicenter.com/drugs/vk2735--chronic-weight-management/executive-summary) · [Markdown](https://www.evicenter.com/drugs/vk2735--chronic-weight-management/executive-summary.md)
- [VK2735 in Chronic weight management: Product information and disease description](https://www.evicenter.com/drugs/vk2735--chronic-weight-management/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/vk2735--chronic-weight-management/product-information-and-disease-description.md)
- [VK2735 in Chronic weight management: Clinical evidence](https://www.evicenter.com/drugs/vk2735--chronic-weight-management/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/vk2735--chronic-weight-management/clinical-evidence.md)
- [VK2735 in Chronic weight management: Economic information and modeling report](https://www.evicenter.com/drugs/vk2735--chronic-weight-management/economics) · [Markdown](https://www.evicenter.com/drugs/vk2735--chronic-weight-management/economics.md)
- [VK2735 in Chronic weight management: References](https://www.evicenter.com/drugs/vk2735--chronic-weight-management/references) · [Markdown](https://www.evicenter.com/drugs/vk2735--chronic-weight-management/references.md)
